Acute Myelomonocytic Leukemia Symptoms, Doctors, Treatments, Advances & More

Learn About Acute Myelomonocytic Leukemia

View Main Condition: Leukemia

What is the definition of Acute Myelomonocytic Leukemia?

A rare acute myeloid leukemia disorder characterized by increased blast cells (myeloblasts, monoblast, and/or promonoblasts), representing more than 20% of the total bone marrow (BM) or peripheral blood differential counts, with 20-80% of BM cells being of monocytic lineage. Clinical presentation is the result of bone marrow involvement and extramedullary infiltration by the leukemic cells and includes asthenia, pallor, fever, dizziness, respiratory symptoms, easy bruising, bleeding disorders, and neurological deficits. Gingival hyperplasia, organomegaly, especially hepatosplenomegaly, and lymphadenopathy may also be associated.

Save information for later

What are the alternative names for Acute Myelomonocytic Leukemia?

Acute myelomonocytic leukemia
Acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
AML M4
AML-M4
AMMoL
Acute myeloblastic leukemia type 4
AML with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22)
Acute myelomonocytic leukemia
CBFB-MYH11

Who are the top Acute Myelomonocytic Leukemia Local Doctors?

Dr. Mikkael A. Sekeres

Hematology Oncology | Hematology | Oncology

Elite

Highly rated in

conditions

Hematology Oncology
Hematology
Oncology

University of Miami Health System

University Of Miami

1475 Nw 12th Ave,

Miami, FL

Mikkael Sekeres is a Hematologist Oncology specialist and a Hematologist in Miami, Florida. Sekeres has been practicing medicine for over 27 years and is rated as an Elite expert by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 25 other conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant. Sekeres is currently accepting new patients.

Lionel Ades

Elite

Highly rated in

conditions

Hôpital Saint Louis

Paris, FR

Lionel Ades practices in Paris, France. Ades is rated as an Elite expert by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 13 other conditions, according to our data. His top areas of expertise are Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML), Leukemia, and Bone Marrow Transplant.

Learn about our expert tiers

Learn more

Dr. Douglas V. Faller

Hematology

Elite

Highly rated in

conditions

Hematology

Boston Medical Center

830 Harrison Ave,

Boston, MA

Douglas Faller is a Hematologist in Boston, Massachusetts. Faller has been practicing medicine for over 44 years and is rated as an Elite expert by MediFind in the treatment of Acute Myelomonocytic Leukemia. He is also highly rated in 6 other conditions, according to our data. His top areas of expertise are Acute Myelomonocytic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome (MDS), and Acute Myeloid Leukemia (AML).

View All Doctors

What are the latest Acute Myelomonocytic Leukemia Clinical Trials?

A Phase I/II Study of Venetoclax in Combination With Azacitidine in Relapsed/Refractory High-Risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML)

Who is this study for: Adult patients with Chronic Myelomonocytic Leukemia or Myelodysplastic Syndrome

Enrollment Status: Recruiting

Publish Date: February 13, 2023

Intervention Type: Drug

Study Drugs: AzacitidineVenetoclax

Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial investigates the side effects and best dose of venetoclax when given together with azacitidine and to see how well it works in treating patients with high-risk myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back (relapsed) or has not responded to treatment (refractory). Venetoclax may stop the growth of cancer cells by blocking some of the enzymes n...

Match to trials

Find the right clinical trials for you in under a minute

Get started

Phase II Study of Clofarabine and High-Dose Melphalan Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation for Myelodysplasia or Acute Leukemia in Remission

Who is this study for: Adult patients with Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

Enrollment Status: Active, not recruiting

Publish Date: February 09, 2023

Intervention Type: Procedure, Drug, Other

Study Drugs: ClofarabineMelphalanTacrolimusSirolimus

Study Phase: Phase 2

Summary: This phase II trial studies how well clofarabine and melphalan before a donor stem cell transplant works in treating patients with a decrease in or disappearance of signs and symptoms of myelodysplasia or acute leukemia (disease is in remission), or chronic myelomonocytic leukemia. Giving chemotherapy, such as clofarabine and melphalan, before a donor stem cell transplant helps stop the growth of ...

View All Clinical Trials

Who are the sources who wrote this article ?

Published Date: May 02, 2022
Published By: Genetic and Rare Diseases Informnation Center

What are the Latest Advances for Acute Myelomonocytic Leukemia?